GlassScriptPhysician profile
Joseph Jozic
NPI 1700863149
$12,133.80
in general payments reported to CMS, 2019-2025
25 companies · $443 in 2025
The $443 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,221 · 2020: $1,009 · 2021: $539 · 2022: $317 · 2023: $687 · 2024: $917 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,047.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $8,513.42 | 2019-2025 | Diamondback Coronary, Amplatzer Amulet, Dragonfly Opstar |
| Edwards Lifesciences Corporation | $1,384.94 | 2020-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medtronic, INC. | $306.38 | 2021-2025 | Corevalve Evolut R, Onyx Frontier, Symplicity G3 |
| Novartis Pharmaceuticals Corporation | $279.13 | 2020-2024 | |
| Abiomed | $242.55 | 2019-2025 | Impella |
| Zoll Circulation INC | $204.92 | 2023 | Downstream Cartridge, Catheter, Therox Ds2 Console |
| Teleflex LLC | $201.88 | 2019-2024 | Manta |
| Astrazeneca Pharmaceuticals LP | $150.58 | 2019-2023 | Farxiga |
| Shockwave Medical, INC | $122.29 | 2021 | |
| Pfizer INC. | $97.69 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $96.76 | 2021 | |
| Medtronic Vascular, INC. | $72.04 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $63.38 | 2020-2025 | Lifevest |
| Cordis US Corp. | $50.95 | 2022 | |
| Boston Scientific Corporation | $50.32 | 2020-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $45.34 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $44.55 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $44.34 | 2019-2022 | |
| Amgen INC. | $34.72 | 2020-2023 | Repatha |
| Kiniksa Pharmaceuticals, LTD. | $31.87 | 2023 | Arcalyst |
| Kestra Medical Technology Services, INC. | $29.89 | 2024 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $18.45 | 2024 | Arcalyst |
| Biotronik INC. | $17.30 | 2023 | Trapit, Recross, Pk Papyrus |
| Terumo Medical Corporation | $17.23 | 2022 | |
| Esperion Therapeutics, INC. | $12.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Jozic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.